FDA is taking a strict view of the evidence for claims of abuse-deterrence with new opioid formulations. While the agency and industry agree on the public health need, abuse-deterrent opioids have been the products most likely to miss user fee goal dates in the past year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?